Short-term efficacy and safety of sacituzumab govitecan in posterior-line therapy for advanced malignant tumors
10.3760/cma.j.cn115355-20240205-00069
- VernacularTitle:戈沙妥珠单抗后线治疗晚期恶性肿瘤的近期效果及安全性
- Author:
Yang WANG
1
;
Chaonan HUANGFU
1
;
Zhining WANG
1
Author Information
1. 南京明基医院肿瘤科，南京 210000
- Publication Type:Journal Article
- Keywords:
Neoplasm;
Immunoconjugates;
Antibodies, monoclonal, humanized;
Treatment outcome;
Adverse reactions;
Sacituzumab govitecan;
Posterior-line therapy
- From:
Cancer Research and Clinic
2025;37(3):186-189
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the efficacy and adverse reactions of sacituzumab govitecan (SG) in the posterior-line therapy for advanced malignant tumors.Methods:A retrospective case series study was conducted. The clinicopathological data of 20 patients with advanced malignant tumors who were treated with SG after multiple lines of treatment in Nanjing BenQ Hospital From July to December 2023 were retrospectively analyzed. The short-term efficacy and treatment-related adverse events (TRAE) were evaluated.Results:Among the 20 patients, there were 7 males and 13 females, the median age [ M ( Q1, Q3)] was 60.0 (53.8, 72.5) years old, the median line of previous anti-tumor regimens was 4.5 (3.3, 6.0) lines, and the median duration time of SG treatment was 52.5 (35.8, 72.5) days. After SG treatment, there were 3 cases (15.0%) with partial response, including breast cancer, vaginal squamous cell carcinoma and endometrial carcinoma, 10 cases (50.0%) with stable disease and 7 cases (35.0%) with progressive disease. The objective response rate was 15.0% (3/20), and the disease control rate was 65.0% (13/20). Two cases (10.0%) were discontinued due to intolerable adverse reactions. The incidence of TRAE was 75.0% (15/20), of which the incidence of ≥grade 3 TRAE was 10.0% (2/20), including neutropenic fever and ventricular arrhythmia. Conclusions:SG has a certain therapeutic effect and controllable safety in the posterior-line therapy for advanced malignant tumors.
